GynEC®-DX: a new diagnostic test for Endometrial Cancer.
Endometrial cancer is cancer that forms in the lining of the uterus. It is the most frequent genital cancer in women worldwide, with about 300,000 new cases reported annually. In the U.S. and Europe-27, it is the gynecological cancer with the highest incidence with 40,000 and 57,000 new cases reported each year, respectively [source: GLOBOCAN 2008 v1.2, available at http://globocan.iarc.fr].
In Spain, about 4,400 women are diagnosed with this disease each year.
One of the main symptoms of the disease is the occurrence of uterine bleeding after menopause. Endometrial cancer is treated with good results if it is early detected.
GynEC®-DX is a product developed by GEADIC BIOTEC AIE, joint venture between ORYZON and Reig Jofre Group, and is based on the expression of five genes discovered in collaboration with the Hospital Vall d'Hebron of Barcelona. The discovery of these biomarkers was published in the International Journal of Cancer.
The product was validated in a multicenter clinical trial on double-blind which involved 14 Spanish hospitals, among them the Spanish network of translational research in Gynecologic Oncology, "REDITOG", and Vall d'Hebron Hospital. The study was coordinated by Dr. Jordi Ponce, and Dr. Antonio Gil.
Clinical trial results were presented at the Congress of ESGO in Milan in September 2011 (poster).
GynEC®-DX is a product protected by international patents.